Atmos Energy Corporation vs Gilead Sciences, Inc. — how do they compare? Atmos Energy Corporation trades at $168.76 (market cap $28.38B), while Gilead Sciences, Inc. trades at $135.89 (market cap $164.99B). The key difference: Gilead Sciences, Inc. is far larger — about 5.8× Atmos Energy Corporation's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.47%). Which is the better fit depends on your goals.
| ATO | GILD | |
|---|---|---|
Market Cap | $28.38B | $164.99B |
Sector | Utilities | Health |
52-Week High | $192.25 | $155.80 |
52-Week Low | $162.44 | $110.56 |
Enterprise Value | $38.18B | $188.06B |
Dividend Yield | 2.38% | 2.47% |
Signals from Pluang's Aura AI — not financial advice
Atmos Energy (ATO) trades at $170.19, down 1.04% today, with a bearish technical signal despite recent earnings beats. The company reported Q2 2026 EPS of $1.43, beating expectations by 5.9%, and maintains strong fundamentals with 28.5% net income margin and $4.70B revenue. Recent board appointments and dividend declarations highlight corporate stability, while analyst consensus targets $190.57 with 45% buy ratings.
ATO presents a mixed outlook with solid earnings growth and dividend stability offset by bearish technical indicators and negative cash flow trends. The stock offers value through consistent profitability and infrastructure investments, though investors face risks from high capital expenditures and debt levels that could pressure future returns.
Gilead Sciences (GILD) trades at $133.21, up 1.8% in the last session, with a bullish technical outlook and strong analyst support. Recent Q2 2026 results showed a revenue beat despite a net loss driven by acquisition costs, with HIV drug sales and pipeline progress fueling raised full-year guidance. The stock exhibits robust cash flow from operations and a high gross margin, though negative net income and elevated debt levels present fundamental concerns.
The outlook is positive based on raised sales guidance and pipeline momentum, but risks include patent cliffs for key HIV drugs by the mid-2030s and integration challenges from recent acquisitions. With a consensus price target of $151.22 implying 13.5% upside, Wall Street sentiment is bullish, though investors should weigh growth prospects against execution and regulatory risks.
Trailing returns across standard periods
Latest headlines on both assets
Atmos Energy is the largest publicly traded, fully regulated, pure-play natural gas utility in the United States, serving more than 3 million customers in Texas, Colorado, Kansas, Kentucky, Louisiana, Mississippi, Tennessee, and Virginia. About two thirds of its earnings come from Texas, where it distributes natural gas in northern Texas and owns an intrastate gas pipeline spanning several key shale gas formations and interconnected with five storage facilities.
Read more on ATO →Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →